Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Sputum positive for tubercule bacilli (at least 1+ on the International Union Against Tuberculosis and Lung Disease \[IUATLD\]/WHO scale (Appendix 1) on smear microscopy) at the trial laboratory.~* Participants with one of the following pulmonary TB conditions:~DS-TB treatment arm participants should be:~* sensitive to rifampicin and isoniazid by rapid sputum based test AND~* either newly diagnosed for TB or have a history of being untreated for at least 3 years after cure from a previous episode of TB.~DR-TB treatment arm participants should be Resistant to rifampicin and/or isoniazid.~* Of non-childbearing potential or willing to practice effective methods of birth control~* Body weight (in light clothing and no shoes) ≥ 30 kg.~* Completed informed consent form~Exclusion Criteria:~* Karnofsky score \<60%~* Any risk factor for QT prolongation~* Any planned contraindicated medicines~* Resistant to fluoroquinolones (rapid, sputum-based molecular screening tests).~Any of the following lab toxicities/abnormalities:~* CD4+ count \< 100 cells/µL (HIV infected participants)~* platelets \<75,000/mm³~* creatinine \>1.5 times upper limit of normal (ULN)~* eGFR ≤ 60 mL/min~* haemoglobin \<8.0 g/dL~* serum potassium less than the lower limit of normal for the laboratory.~* GGT: greater than 3 x ULN~* AST: ≥3.0 x ULN to be excluded;~* ALT: ≥3.0 x ULN to be excluded~* ALP: ≥3.0 x ULN to be excluded~* Total bilirubin: \>1.5 x ULN to be excluded;~* Direct bilirubin: greater than 1x ULN to be excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug Sensitive BPaMZ (Type: EXPERIMENTAL): Bedaquiline 200 mg daily for 8 weeks then 100 mg daily for 9 weeks, together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg daily for 17 weeks (Total treatment duration 4 months
- Drug Sensitive Standard Treatment (Type: ACTIVE_COMPARATOR): isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9 to 26
- Drug Resistant BPaMZ (Type: EXPERIMENTAL): Bedaquiline 200 mg daily for 8 weeks then 100 mg daily for 18 weeks, together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg daily for 26 weeks (Total treatment duration 6 months)

Based on this trial design, predict the completion outcome and termination type (if applicable).